Literature DB >> 34826050

Immunotherapeutic role of cabazitaxel treatment in the activation of TLR3 signalling in metastatic castration-resistant prostate cancer in vitro.

Asuman Deveci Ozkan1, Gamze Guney Eskiler2, Suleyman Kaleli2, Elvan Sahin3.   

Abstract

BACKGROUND: The activation of toll like receptors (TLR) potentially affect the inflammatory tumor microenvironment and thus is associated with tumor growth or inhibition. Cabazitaxel (CAB) has been effectively used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, the immune regulatory role of CAB in the tumor microenvironment is not clear. In this context, we for the first time assessed the immunotherapeutic role of CAB in the TLR3 signalling following activation of Poly I:C in mCRPC cells. METHODS AND
RESULTS: The cytotoxic and apoptotic effects of CAB with the induction of Poly I:C were determined by WST-1, Annexin V, acridine orange, RT-PCR analysis, ELISA assay and immunofluorescence staining in DU-145 mCRPC and HUVEC control cells. Our findings showed that CAB treatment with Poly I:C significantly suppressed the proliferation of DU-145 cells through the induction of apoptosis and caspase activation. Additionally, higher concentration of CAB mediated the activation of TLR3 via increased cytoplasmic and nuclear expression of TLR3, TICAM-1 and IRF-3 in mCRPC cells.
CONCLUSIONS: Co-treatment of CAB and Poly I:C was more effective in mCRPC cells with less toxicity in control cells. However, further investigations are required to elucidate the molecular mechanisms of TLRs signalling upon CAB treatment at the molecular level to further validate the immunotherapeutic efficacy of CAB in mCRPC.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; Cabazitaxel; Taxanes; Toll like receptor 3; Toll like receptors

Mesh:

Substances:

Year:  2021        PMID: 34826050     DOI: 10.1007/s11033-021-06953-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

Review 1.  Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR).

Authors:  Antonio Tito Fojo; Michael Menefee
Journal:  Semin Oncol       Date:  2005-12       Impact factor: 4.929

2.  Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

Authors:  V Diéras; A Lortholary; V Laurence; R Delva; V Girre; A Livartowski; S Assadourian; D Semiond; J Y Pierga
Journal:  Eur J Cancer       Date:  2012-09-10       Impact factor: 9.162

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

Review 5.  Secondary hormonal therapy for advanced prostate cancer.

Authors:  John S Lam; John T Leppert; Sreenivas N Vemulapalli; Oleg Shvarts; Arie S Belldegrun
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

Review 6.  Cabazitaxel in metastatic castration-resistant prostate cancer.

Authors:  Timothy A Yap; Carmel J Pezaro; Johann S de Bono
Journal:  Expert Rev Anticancer Ther       Date:  2012-09       Impact factor: 4.512

7.  Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

Authors:  Alain C Mita; Louis J Denis; Eric K Rowinsky; Johann S Debono; Andrew D Goetz; Leonel Ochoa; Bahram Forouzesh; Muralidhar Beeram; Amita Patnaik; Kathleen Molpus; Dorothée Semiond; Michèle Besenval; Anthony W Tolcher
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.

Authors:  Tian Yi Zhang; Neeraj Agarwal; Guru Sonpavde; Giuseppe DiLorenzo; Joaquim Bellmunt; Nicholas J Vogelzang
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 2.862

9.  ERG induces taxane resistance in castration-resistant prostate cancer.

Authors:  Giuseppe Galletti; Alexandre Matov; Himisha Beltran; Jacqueline Fontugne; Juan Miguel Mosquera; Cynthia Cheung; Theresa Y MacDonald; Matthew Sung; Sandra O'Toole; James G Kench; Sung Suk Chae; Dragi Kimovski; Scott T Tagawa; David M Nanus; Mark A Rubin; Lisa G Horvath; Paraskevi Giannakakou; David S Rickman
Journal:  Nat Commun       Date:  2014-11-25       Impact factor: 14.919

Review 10.  Preclinical profile of cabazitaxel.

Authors:  Patricia Vrignaud; Dorothée Semiond; Veronique Benning; Eric Beys; Hervé Bouchard; Sunil Gupta
Journal:  Drug Des Devel Ther       Date:  2014-10-13       Impact factor: 4.162

View more
  1 in total

1.  Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening.

Authors:  Haijiang Dong; Zequn Li; Suchen Bian; Guangyuan Song; Wenfeng Song; Mingqi Zhang; Haiyang Xie; Shusen Zheng; Xuxu Yang; Tiefeng Li; Penghong Song
Journal:  Bioact Mater       Date:  2022-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.